Randomized Controlled Trial of Huanglian Jiedu Decoction in Improving Cognitive Function and Neuroinflammation in Patients with Vascular Dementia

Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i1.3677

Mingyue Cui1, Leilei Wang2, Tingting Wang2, Zhixing Chen2, Youxiang Cui2

1. Nantong Hospital of Traditional Chinese Medicine, Nantong 226001, Jiangsu, China
2. Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Cangzhou 061000, Hebei, China

Abstract

Background and Objective: Huanglian Jiedu Decoction (HLJD) is commonly used for patients with vascular dementia (VaD) in China. Objective: To evaluate the clinical efficacy of HLJD through a randomized controlled trial (RCT). Methods: The control group received Donepezil Hydrochloride tablets, while the experimental group received Donepezil Hydrochloride tablets combined with HLJD. Both groups were treated for 8 weeks. The clinical efficacy and incidence of adverse reactions were compared between the two groups. The MMSE and MoCA scales were used to assess cognitive function. Inflammatory cytokines IL-6, IL-1β, TNF-α, and hs-CRP were also compared. Results: After treatment, the effective rate in the control group was 28.13%, while the effective rate in the experimental group was 56.67%, significantly higher than that in the control group (P<0.05). After treatment, the MMSE and MoCA scores of both groups increased significantly compared to baseline (P<0.01). The MMSE score in the experimental group was higher than that in the control group (P<0.01), and the MoCA score in the experimental group was also higher than that in the control group (P<0.05). After treatment, the levels of inflammatory cytokines IL-6, IL-1β, TNF-α, and hs-CRP in both groups decreased significantly compared to baseline (P<0.01). The experimental group showed better results in reducing the levels of these inflammatory cytokines than the control group (P<0.01). Additionally, the total clinical efficacy rate in the experimental group was 96.00%, higher than the 82.00% in the control group (P<0.05). Conclusion: HLJD combined with Donepezil can provide symptomatic benefits for patients with mild to moderate VaD.

Keywords

Vascular dementia, Huanglian Jiedu Decoction, Randomized Controlled, TrialInflammatory factors, Cognitive function

References

[1] Morgan A E, Mc A M. Vascular dementia: From pathobiology to emerging perspectives[J]. Ageing Res Rev. 2024, 96: 102278.
[2] Chang W E, Chang C H. Vascular Cognitive Impairment and Dementia[J]. Continuum (Minneap Minn). 2022, 28(3): 750-780.
[3] Jiao C, Wei S, Liu T, et al. The Prevalence of Vascular Dementia in China: A Systematic Review and Meta-Analysis from 2009-2019[J]. Iran J Public Health. 2021, 50(1): 11-23.
[4] Roman G C, Tatemichi T K, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop[J]. Neurology. 1993, 43(2): 250-260.
[5] Folstein M F, Folstein S E, Mchugh P R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res. 1975, 12(3): 189-198.
[6] Gottesman R F, Hillis A E. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke[J]. Lancet Neurol. 2010, 9(9): 895-905.
[7] Wang X X, Zhang B, Xia R, et al. Inflammation, apoptosis and autophagy as critical players in vascular dementia[J]. Eur Rev Med Pharmacol Sci. 2020, 24(18): 9601-9614.
[8] Tian Z, Ji X, Liu J. Neuroinflammation in Vascular Cognitive Impairment and Dementia: Current Evidence, Advances, and Prospects[J]. Int J Mol Sci. 2022, 23(11).
[9] Xing S H Z C. Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis.[J]. Evidence-Based Complementray and Alternative Medicine. 2014 (2014): 363985.
[10] Bar K J, Boettger M K, Seidler N, et al. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy[J]. Stroke. 2007, 38(12): 3186-3192.
[11] Kandiah N, Pai M C, Senanarong V, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia[J]. Clin Interv Aging. 2017, 12: 697-707.
[12] Appleton J P, Scutt P, Sprigg N, et al. Hypercholesterolaemia and vascular dementia[J]. Clin Sci (Lond). 2017, 131(14): 1561-1578.
[13] Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia[J]. Cochrane Database Syst Rev. 2019, 2019(11).
[14] Sowndhararajan K, Deepa P, Kim M, et al. Neuroprotective and Cognitive Enhancement Potentials of Baicalin: A Review[J]. Brain Sci. 2018, 8(6).
[15] Wang Z, Yang Y, Liu M, et al. Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review[J]. Curr Vasc Pharmacol. 2020, 18(4): 358-368.

Copyright © 2025 Mingyue Cui, Leilei Wang, Tingting Wang, Zhixing Chen, Youxiang Cui

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License